Perspectives

WuXi Biologics CEO Chris Chen: In the Era of Complex Molecules, Innovators Need CDMOs with Specialized and Integrated Capabilities

Jun. 08, 2026

WuXi Biologics CEO Chris Chen: In the Era of Complex Molecules, Innovators Need CDMOs with Specialized and Integrated Capabilities

As biopharmaceutical innovation accelerates, drug development is shifting from monoclonal antibodies toward more complex and diverse molecular types. Next-generation therapies such as bispecific and multispecific antibodies and antibody–drug conjugates (ADCs) are rapidly emerging, raising the bar for development and manufacturing capabilities. At the same time, different molecular types present distinct requirements in process development, quality control, and large-scale production, reshaping the CDMO landscape.

In response, CDMOs are moving beyond a focus on capacity and general capabilities, toward differentiated models built on molecular expertise, technical depth, and integrated service capability.

Against this backdrop, Dr. Chris Chen, CEO of WuXi Biologics, was recently interviewed by Pharma’s Almanac, where he shared his perspectives on how increasing molecular complexity is driving the evolution of the CDMO industry.

Below is the excerpt of Dr. Chen’s viewpoints. Click here to read the original interview content.

Pharma’s Almanac:

How is the increasing complexity of modalities reshaping CDMO differentiation and specialization strategies?

Dr. Chris Chen:

The rapid rise of complex modalities is raising the bar for CDMO differentiation. The focus is no longer on capacity or cost alone, but on the ability to systematically de-risk development and industrialize complexity — from discovery through CMC, tech transfer, and commercial supply. Across the industry, we see growing demand for complex antibodies, conjugates, and advanced therapies that require domain expertise, dedicated technologies, and strong cross-functional integration.

We believe the winning model is an integrated, end-to-end CRDMO platform that combines deep specialization with seamless execution. Rather than managing multiple partners, innovators need a single partner with proven experience in complex modalities and the ability to advance programs efficiently with fewer handoffs. This shift is reflected in our integrated projects: in 2025, we added 209 new integrated projects, with two-thirds in complex biologics. This underscores a broader trend — particularly for complex modalities, the efficient pipeline advancement increasingly depends on specialized, integrated CRDMO capabilities.

At the same time, complexity is redefining what service means. Flexibility and agility are becoming critical, as advanced therapies are often marked by variable demand and evolving processes. This requires not only scalable, right-sized manufacturing solutions, but also flexible service models and accelerated development timelines — for example, enabling CMC development for complex molecules such as bispecific antibodies in as fast as six months. Digitalization capabilities are becoming a key differentiator — enabling better process insight, faster decision making, and more reliable manufacturing.

Ultimately, CDMOs that combine technical depth, integrated solutions, and digital capabilities will be best positioned to make scientific complexity more predictable and deliverable, translate innovation into accessible therapies for patients.

List